Genmab A/S

GMAB Nasdaq SEC CIK 1434265
Follow Genmab Weekly email: filings, results, news

Financials

Reported figures only · latest: Q4 2024 DKK · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income10 fiscal years
  • Revenue
  • Net income
DKK 0DKK 10BDKK 20BDKK 30BFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25--
FY24DKK 21.5BDKK 7.8B
FY23DKK 16.5BDKK 4.4B
FY22DKK 14.5BDKK 5.5B
FY21DKK 8.4BDKK 3B
FY20DKK 10.1BDKK 4.8B
FY19DKK 5.4BDKK 2.2B
FY18DKK 3BDKK 1.5B
FY17DKK 2.4BDKK 1.1B
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
0%20%40%60%80%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY2431.1%36.4%
FY2332.3%26.4%
FY2243.2%37.6%
FY2135.1%35.1%
FY2062.4%47.1%
FY1949.2%40.4%
FY1845.6%48.7%
FY1756.8%46.7%
FY16--
Free cash flowOperating cash flow minus capital expenditure
DKK 0DKK 2BDKK 4BDKK 6BDKK 8BFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24DKK 7.6B
FY23DKK 7B
FY22DKK 3.6B
FY21DKK 2B
FY20DKK 6.1B
FY19DKK 1.2B
FY18DKK 943M
FY17DKK 1.5B
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Genmab
  • Healthcare median
−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearGenmabHealthcare median
FY25-−63.2%
FY2436.4%−86.4%
FY2326.4%−123.6%
FY2237.6%−138.2%
FY2135.1%−139.8%
FY2047.1%−143.7%
FY1940.4%−143.3%
FY1848.7%−173.4%
FY1746.7%−166.7%
FY16-−173.8%

News

5 stories filed under Genmab, grouped into ongoing threads